Fault-tolerant quantum computing has become the organizing goal of the entire quantum-hardware industry, and its patent landscape is distinctive because the central problem is not building more qubits but building qubits that stay correct while computing. Fault-tolerant quantum computing combines many noisy physical qubits into one error-protected logical qubit through a quantum error-correcting code, with the goal of "below-threshold" operation, where adding more physical qubits per logical qubit exponentially suppresses the logical error rate rather than accumulating it. Google's Quantum AI team demonstrated this directly on a superconducting processor: scaling a surface code from distance-3 to distance-5 to distance-7 suppressed the logical error rate by roughly a factor of two per code-distance increment, with the resulting logical qubit's lifetime exceeding that of its best constituent physical qubit — the first hardware-scale confirmation of below-threshold scaling¹. On neutral-atom hardware, a Harvard/MIT/QuEra collaboration demonstrated a logical quantum processor with up to 48 logical qubits and reconfigurable connectivity, performing transversal operations — a milestone that is substantially error-detected and algorithmic in character rather than a fully fault-tolerant computation with continuous real-time correction². Trapped-ion platforms have separately demonstrated real-time logical-qubit error detection and correction³. The intellectual property divides across several regions, each a distinct area of patenting: the qubit modality itself, including superconducting circuits, trapped ions, neutral atoms, photonic qubits, and bosonic (cat) qubits; the error-correcting code, including the mature surface code and the newer quantum low-density parity-check (qLDPC) codes, which promise a substantially better ratio of logical to physical qubits at the cost of the non-local connectivity they require — a constraint that recent work specifically targets with 2D-local implementations⁴,⁵; the real-time decoding hardware and software that must detect and correct errors fast enough to keep pace with computation, an area seeing progress in network-integrated decoding for lattice surgery at scale⁶; and the interconnect and networking technology needed to link separate processors, an approach with early metropolitan-scale demonstrations, including work toward entanglement swapping across roughly 30 kilometers in a three-node network in New York City⁷. Because a competitive fault-tolerant architecture depends on all of these layers working together, and because different companies are betting on different qubit modalities, freedom-to-operate and white space analysis must span modality and code together.

Bosonic, or "cat," qubits are a distinct and increasingly well-evidenced hardware-efficiency route: by engineering the qubit itself to exponentially suppress bit-flip errors as a function of mean photon number, cat-qubit architectures convert the correction problem into one of handling a biased, phase-flip-dominated error channel, with experimental bit-flip times pushed past ten seconds in one demonstration⁸. Multiple hardware vendors have published multi-year roadmaps that should be read as stated targets rather than achieved milestones: IBM's own roadmap targets a system called Starling for 2029, running 100 million gates on 200 logical qubits, while Quantinuum's own roadmap targets a universal, fully fault-tolerant system by the end of the decade⁹. Because applications publish about eighteen months after filing, the newest decoder, qLDPC-code, and interconnect filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic question is which layer of the stack a given owner can actually defend, and the white space sits where engineering, not physics, is now the bottleneck. Qubit-modality IP is comparatively mature and fragmented across several well-funded, differently architected companies, so no single modality currently dominates the landscape. The faster-moving and more open ground is in error-correcting-code implementation — particularly qLDPC codes, which are newer and less thoroughly claimed than the surface code, and whose central practical obstacle (non-local connectivity) is itself an active area of new filings — real-time classical decoding hardware, which must operate fast enough not to become the new bottleneck once qubits themselves are reliable, and quantum networking, which several companies are pursuing as an alternative to scaling a single monolithic chip. Reading the landscape by modality, code, and layer, and tracking both the patents and the underlying quantum-information-science research, is what separates a defensible architectural bet from a crowded one.

Where the fault-tolerant quantum computing white space is

Quantum LDPC codes and their connectivity solutions. Codes promising a better logical-to-physical-qubit ratio than the surface code are newer and less thoroughly claimed, and the 2D-local implementations needed to make them practical are themselves an active, comparatively open filing area⁴,⁵.

Real-time decoding hardware and software. Classical decoders that detect and correct errors fast enough to keep pace with a scaling quantum processor are an increasingly critical, comparatively open layer⁶.

Bosonic and cat-qubit architectures. Hardware-efficient codes that build error protection into the physical qubit itself, reducing the number of physical qubits needed per logical qubit, remain a less-crowded alternative to surface-code-based approaches⁸.

Quantum networking and multi-node architectures. Linking separate quantum processors — including early metropolitan-scale demonstrations over standard fiber-optic infrastructure — is an emerging alternative to monolithic scaling, with comparatively little settled IP⁷.

Verified, primary-sourced roadmap claims. Because most public logical-qubit and gate-count targets are company roadmap statements rather than demonstrated results, an owner able to substantiate claims against peer-reviewed, independently reproducible results has a genuine differentiation and credibility advantage.

How AI-powered landscape and white space analysis helps

Resolving a landscape that spans five-plus qubit modalities, several competing error-correcting codes, and the classical and networking engineering needed to scale them requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by modality, code, and layer across varied and fast-evolving terminology, attribution that normalizes hardware-vendor, national-lab, and university filers to canonical entities, and continuous monitoring that keeps pace with a field where major technical milestones are being announced multiple times per year. Because quantum-information-science advances appear in physics literature and preprints before they are patented, reading both patents and literature gives the earliest signal of which code and modality combination is actually closing the gap to fault tolerance — and helps separate demonstrated results from roadmap targets.

The competitive landscape by the numbers

Cypris's corpus puts the quantum error correction / fault-tolerant quantum computing patent family set at roughly 11,928 documents, heavily concentrated in the United States (approximately 5,076 families), followed by China (approximately 1,655) and Canada (approximately 561) (Cypris corpus, indicative; 2025–26 partial). Filing activity has accelerated sharply, from roughly 578 new families in 2020 to about 2,328 in 2025, with 2026 partial at approximately 1,791 (Cypris corpus, indicative; 2025–26 partial). Top assignees are led by superconducting and gate-model incumbents alongside quantum-native firms — Google, IBM, Microsoft, D-Wave, and Rigetti — with Yale, IonQ, Harvard, and MIT also present in the assignee list (Cypris corpus, indicative; 2025–26 partial). A clean split of this corpus by qubit modality and by code/decoder/interconnect layer was not available from this pass; the assignee mix, however, skews toward superconducting and trapped-ion players, consistent with where the demonstrated hardware results described above are concentrated.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving, deep-technical fields such as fault-tolerant quantum computing across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by qubit modality, superconducting, trapped-ion, neutral-atom, photonic, and bosonic, and by layer, error-correcting code, decoding hardware, and interconnect, and normalizes hardware-vendor, national-lab, and university filers to canonical entities, so a team can resolve which modalities and layers are crowded and which remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying quantum-information-science research, which is where fault-tolerance advances appear first, often well ahead of the patent record. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined modality or layer over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

What is fault-tolerant quantum computing? Fault-tolerant quantum computing encodes one error-protected "logical" qubit across many noisy physical qubits using a quantum error-correcting code, targeting "below-threshold" operation, where scaling the code exponentially suppresses the logical error rate. Google demonstrated this directly on superconducting hardware, showing logical error rate falling by roughly 2x per code-distance increment with a logical qubit outliving its best physical qubit¹. It is the prerequisite for running large, reliable quantum programs.

What qubit modalities does the landscape cover? The landscape covers superconducting circuits, trapped ions, neutral atoms, photonic qubits, and bosonic (cat) qubits, each with different native error rates, connectivity, and scaling challenges. No single modality currently dominates the field; Cypris's corpus shows assignees spanning superconducting incumbents (Google, IBM, D-Wave, Rigetti) and trapped-ion and academic players (IonQ, Yale, Harvard, MIT). Each modality is pursued by a differently architected set of developers.

What is a logical qubit, and how many have actually been demonstrated? A logical qubit is an error-protected unit of quantum information built by combining many physical qubits under an error-correcting code. As of the most recent peer-reviewed demonstrations, a neutral-atom platform has shown up to 48 logical qubits with reconfigurable connectivity in an error-detected, largely algorithmic demonstration², and superconducting hardware has demonstrated below-threshold scaling on a smaller logical-qubit count¹. These are well short of the hundreds to thousands of logical qubits that company roadmaps target for the end of the decade⁹.

What claim types create IP activity in fault-tolerant quantum computing? Four layers generate the bulk of IP activity: qubit-modality hardware, error-correcting-code implementation (including the connectivity solutions that make qLDPC codes practical), real-time decoding hardware and software, and interconnect and networking technology. Each is a distinct region of patenting, often held by different companies pursuing different architectural bets. A competitive fault-tolerant system depends on progress across all four.

Where is the white space in fault-tolerant quantum computing? The white space includes qLDPC codes and their connectivity solutions, real-time decoding hardware and software, bosonic/cat-qubit architectures, and quantum networking and multi-node architectures. Qubit-modality IP is comparatively mature and fragmented. The newer error-correcting codes and the classical and networking engineering around them are the most open, high-value ground.

How reliable are company roadmap claims in this field? Company roadmap claims should be read as stated targets, not demonstrated results — IBM's and Quantinuum's own published roadmaps target hundreds to thousands of logical qubits by the end of the decade⁹, well beyond what has been peer-reviewed and demonstrated to date¹,². Distinguishing "demonstrated" from "roadmap target" is essential to reading this field accurately. Analysts and IP teams should trace any specific qubit-count or timeline claim back to its primary source before relying on it.

Why does fault-tolerant quantum computing analysis need scientific literature? Fault-tolerant quantum computing analysis needs scientific literature because error-correcting-code and decoder advances appear in physics research and preprints before they are patented, so the literature gives the earliest signal in a field where major milestones are announced several times a year. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use fault-tolerant quantum computing patent landscape analysis? Fault-tolerant quantum computing patent landscape analysis is used by R&D, IP, and strategy teams at quantum-hardware companies, national laboratories, and technology-company quantum divisions, as well as investors assessing the sector. Because the landscape spans multiple competing qubit modalities and codes at different maturity levels, structured analysis is essential to choosing where to build and where to partner. Cypris serves hundreds of enterprise customers across research-intensive and regulated industries.

Endnotes

1. Bausch J, Malone FD, Martin LS, et al. Quantum error correction below the surface code threshold. Nature. DOI: 10.1038/s41586-024-08449-y.
2. Geim AA, Bluvstein D, Gullans MJ, Kalinowski MW, Maskara N, et al. Logical quantum processor based on reconfigurable atom arrays. Nature. DOI: 10.1038/s41586-023-06927-3.
3. Monroe C, Risinger A, Katz O, Bondurant B, Biswas D. Implementing Real-Time Logical Qubit Error Detection & Correction on a Trapped Ion Quantum Computer. DOI: 10.26226/m.6275705766d5dcf63a311383.
4. Savin V, Vasić B, Raveendran N, Borah SK, Pacenti M. Quantum Low-Density Parity-Check Codes. arXiv. DOI: 10.48550/arxiv.2510.14090.
5. Devulapalli D, Gorshkov AV, Gottesman D, Gullans MJ, Schoute E. Toward a 2D Local Implementation of Quantum Low-Density Parity-Check Codes. PRX Quantum. DOI: 10.1103/prxquantum.6.010306.
6. Liyanage N, Wu Y, Zhong L, Houghton E. Network-Integrated Decoding System for Real-Time Quantum Error Correction with Lattice Surgery. DOI: 10.48550/arxiv.2504.11805.
7. Bigagli N, Shabani J, Namazi M, Cowan TE, Craddock AN. Towards entanglement swapping over 30 km in a three-node metropolitan quantum network in New York City. DOI: 10.1364/quantum.2025.qw4a.7.
8. Albertinale E, Cohen J, Lescanne R, Campagne-Ibarcq P, Sarlette A. Quantum control of a cat qubit with bit-flip times exceeding ten seconds. Nature. DOI: 10.1038/s41586-024-07294-3.
9. IBM Quantum Roadmap (Starling, 2029) and Quantinuum's accelerated roadmap to universal, fully fault-tolerant quantum computing — company technical blogs and press releases.
10. Cypris platform corpus analysis, quantum error correction / fault-tolerant quantum computing patent families. Indicative figures; 2025–2026 partial.

‍

Electrolysis has become the center of gravity in hydrogen innovation, and the electrolyzer patent landscape is where the clean-hydrogen transition is being contested. A joint study of global patent data by the European Patent Office and the International Energy Agency found that technologies motivated by climate concerns accounted for nearly 80 percent of all hydrogen-production patents by 2020, with growth driven chiefly by a sharp increase in innovation in water electrolysis, and that climate-driven hydrogen technologies generated roughly twice as many international patent families as established, fossil-based methods.¹ The commercial backdrop is a projected expansion of electrolyzer manufacturing on the order of a 65-fold increase in market size over the decade, as countries scale low-emissions hydrogen for hard-to-abate sectors.²,³ For R&D and IP teams, the strategic questions are which electrolyzer technology route to back and where defensible IP positions remain, and both are patent-landscape questions.

The landscape divides across four electrolyzer technologies at different maturity levels, each a distinct region of patenting, and each characterized in the US Department of Energy's comparative assessment of solid-oxide, alkaline, and proton-exchange-membrane electrolyzers.⁴ Alkaline electrolysis is the most mature and lowest-cost route, using a liquid alkaline electrolyte and avoiding scarce precious metals, so its patenting concentrates on efficiency, dynamic operation to follow variable renewable power, and stack scale-up. Proton-exchange-membrane (PEM) electrolysis offers compact, responsive operation well suited to variable renewables but relies on scarce platinum-group catalysts and specialized membranes, so a large share of its patenting targets catalyst loading reduction, membrane durability, and cost.⁵ Solid-oxide electrolysis (SOEC) operates at high temperature with high electrical efficiency and can co-electrolyze to produce syngas, but durability and thermal cycling are the central challenges, so patenting concentrates there. Anion-exchange-membrane (AEM) electrolysis is the newest route, aiming to combine PEM-like performance without precious-metal dependence, and it is the least mature and least crowded, which makes it a notable area of white space; its membranes and non-precious-metal catalysts are an active peer-reviewed research frontier.⁶

Geography and institutional origin further shape the landscape. The EPO and IEA analysis found Europe gaining an edge as a location for electrolyzer innovation and manufacturing investment, while Japan led patenting in hydrogen end-use for the automotive sector, and it noted that momentum in other end-use applications, such as aviation, shipping, and power generation, had not yet matched the attention those sectors receive.¹ The European Commission's Joint Research Centre has separately tracked the status of water electrolysis and hydrogen technology in the European Union, corroborating the region's manufacturing push.⁷ It also found that emerging low-emissions hydrogen carriers, including liquid organic hydrogen carriers and ammonia cracking, grew (by about 12.5 percent and 7.8 percent in international patent families respectively) with roughly half of that activity originating in universities and public research, an early-stage signal of where future commercial IP may form.¹ Because applications publish about eighteen months after filing, the most recent activity, particularly in the newer AEM and SOEC routes, is under-represented, so the current frontier is more active than granted-patent counts suggest.

The four electrolyzer routes and where white space sits

Alkaline. The most mature and lowest-cost route, avoiding precious metals; patenting concentrates on efficiency, dynamic operation, and scale-up, so it is comparatively crowded on core design.

PEM. Compact and responsive but reliant on platinum-group catalysts and specialized membranes; white space centers on catalyst reduction, membrane durability, and cost.

SOEC. High-temperature and high-efficiency with co-electrolysis potential, but durability and thermal cycling are the open problems where patenting and white space concentrate.

AEM. The newest route, aiming for PEM-like performance without precious metals; the least mature and least crowded, and therefore a notable area of white space.²

Carriers and end-use. Liquid organic hydrogen carriers and ammonia cracking are early-stage and university-driven, and several end-use sectors beyond automotive remain comparatively under-patented.¹

How AI-powered landscape and white space analysis helps

Resolving four technology routes at different maturities, across geographies and institutions, requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by route and by the problem being solved across varied terminology, attribution that normalizes filers to canonical entities and distinguishes university from commercial activity, and continuous monitoring that tracks the newer routes where recent activity is under-represented. Because electrolyzer advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier and the white space are moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for multi-route energy fields such as hydrogen electrolysis across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by electrolyzer route, alkaline, PEM, SOEC, and AEM, and by the problem being solved, and normalizes filers to canonical entities, so a team can resolve which routes and problems are crowded and which, such as AEM and SOEC durability, remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying materials and engineering research, which is where electrolyzer advances appear first, and distinguishes university from commercial activity. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish, which is essential where the newest routes are under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is electrolysis the focus of hydrogen patenting?

Electrolysis is the focus of hydrogen patenting because it can produce hydrogen with zero direct emissions when powered by renewable or nuclear electricity. A joint EPO and IEA study found that climate-motivated technologies accounted for nearly 80 percent of hydrogen-production patents by 2020, with growth driven chiefly by a surge in electrolysis. Climate-driven hydrogen technologies generated roughly twice the international patent families of established methods.

What are the main electrolyzer technologies?

The main electrolyzer technologies are alkaline, proton-exchange-membrane (PEM), solid-oxide (SOEC), and anion-exchange-membrane (AEM). They differ in maturity, cost, materials, and operating conditions, and each occupies a distinct region of the patent landscape. Alkaline is the most mature and AEM the newest.

Where is the white space in the electrolyzer patent landscape?

The white space in the electrolyzer patent landscape is concentrated in anion-exchange-membrane electrolysis, which is the newest and least crowded route, in solid-oxide durability and thermal cycling, in reducing precious-metal catalyst use and improving membrane durability in PEM, and in early-stage hydrogen carriers such as liquid organic carriers and ammonia cracking. Core alkaline design is comparatively crowded. The higher-value opportunities are in the newer routes and unsolved durability problems.

How do the electrolyzer routes trade off?

The electrolyzer routes trade off maturity, cost, and materials. Alkaline is mature and low-cost but less dynamic; PEM is responsive but relies on scarce platinum-group metals; SOEC is highly efficient but faces durability challenges; and AEM aims to combine PEM-like performance without precious metals but is the least mature. Each route's patenting concentrates on its specific weakness.

How fast is the electrolyzer market expected to grow?

The electrolyzer market is expected to grow rapidly, with the IEA projecting an expansion on the order of a 65-fold increase in market size over the decade as countries scale low-emissions hydrogen. This growth is the commercial driver behind the surge in electrolysis patenting. It also raises the value of securing defensible IP positions early.

Which regions lead electrolyzer innovation?

The EPO and IEA analysis found Europe gaining an edge as a location for electrolyzer innovation and manufacturing investment, while Japan led hydrogen end-use patenting in the automotive sector. Momentum in several other end-use sectors had not yet matched the attention they receive. The geographic distribution differs by technology route and end-use.

Why does electrolyzer analysis need scientific literature?

Electrolyzer analysis needs scientific literature because materials and engineering advances, particularly in catalysts, membranes, and the newer routes, appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view, and much early activity is university-driven. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use electrolyzer patent landscape analysis?

Electrolyzer patent landscape analysis is used by R&D, innovation, IP, and strategy teams at electrolyzer and equipment makers, energy and industrial-gas companies, materials developers, and their partners, as well as investors. It informs which route to back, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

How do you keep an electrolyzer landscape current?

Keeping an electrolyzer landscape current requires continuous monitoring, because the field moves quickly, the newer routes are advancing, and publication lag under-represents the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.

Endnotes

1. European Patent Office & International Energy Agency (2023). Hydrogen patents for a clean energy future: A global trend analysis of innovation along hydrogen value chains. https://www.iea.org/reports/hydrogen-patents-for-a-clean-energy-future
2. International Energy Agency, reported via World Economic Forum (2023). Hydrogen patent filings: Europe and Japan lead on innovation (projected ~65-fold electrolyzer market growth this decade). https://www.weforum.org/stories/2023/03/hydrogen-innovation-patents-technology/
3. International Energy Agency. Global Hydrogen Review (annual series). https://www.iea.org/reports/global-hydrogen-review-2024
4. Kelly, J. C., Elgowainy, A. & Iyer, R. (2022). Electrolyzers for Hydrogen Production: Solid Oxide, Alkaline, and Proton Exchange Membrane. US Department of Energy (OSTI). https://www.osti.gov/
5. US Department of Energy (2024). Hydrogen Shot: Water Electrolysis Technology Assessment. https://www.energy.gov/
6. Zhang, M. et al. (2024). Advanced development of anion-exchange membrane electrolyzers for hydrogen production: from anion-exchange membranes to membrane electrode assemblies. Chemical Communications. https://doi.org/10.1039/D3CC05904A
7. European Commission Joint Research Centre (2023). Water electrolysis and hydrogen in the European Union: Status Report on Technology Development, Trends, Value Chains and Markets. https://publications.jrc.ec.europa.eu/

‍

Energy storage is one of the fastest-growing domains of patenting. A joint analysis by the International Energy Agency and the European Patent Office found that patenting in batteries and electricity storage grew at an average of 14 percent per year between 2005 and 2018, roughly four times faster than the all-technology average, across more than 65,000 international patent families, with batteries accounting for the large majority of electricity-storage patenting.¹ More recent IEA analysis reports that batteries have come to dominate the energy patent landscape.² The drivers are structural: the electrification of transport, the decarbonization of the grid, and the need for long-duration storage to balance intermittent renewable generation. These forces have pushed research and filing activity up sharply across several distinct storage technologies at once, and much of the technology that will define the market at the end of the decade is entering the patent record now.

The energy-storage landscape is not a single field but a set of competing technology routes at different technology-readiness levels, and a rigorous landscape has to segment them. Lithium-ion remains the incumbent, with filing activity concentrated on energy density, fast charging, safety, and cell-to-pack manufacturing. Solid-state batteries have seen filing activity grow several-fold since the late 2010s, and the locus of innovation has shifted from electrolyte materials discovery toward interfacial engineering and scalable manufacturing, a transition documented across recent reviews of all-solid-state commercialization.³,⁴ Within that route, the principal electrolyte classes, sulfide, oxide, polymer, and composite, present different trade-offs: sulfide solid electrolytes reach room-temperature ionic conductivities on the order of 10 to the minus three siemens per centimeter, comparable to conventional liquid electrolytes, but the dominant technical barriers are interfacial resistance, electrochemical stability at the electrode interfaces, dendrite suppression, and scalable synthesis of the electrolyte.³,⁴,⁵ Hydrogen storage, particularly solid-state routes using metal hydrides, has surged as fuel-cell and stationary applications advance, with claim activity concentrated on intermetallic alloy families and multi-phase crystal-structure engineering to balance gravimetric capacity against kinetics and operating pressure. Long-duration and grid-scale storage is an active emerging area, where vanadium redox and other flow batteries, compressed-air storage, iron-air chemistries, and thermal and gravity approaches compete, and a large share of the relevant patents are still pending.

That segmentation is the value of patent landscape and white space analysis for the energy transition. A landscape maps where filing activity concentrates, which routes and sub-classes are crowded, and which organizations are most active; a white space analysis maps where activity is sparse, revealing directions where a defensible position is still available. In a field advancing this quickly, where the architectures that will define the 2030 market are being filed today, the ability to resolve both the dense and the sparse regions, at the level of specific technology routes and sub-classes, and to track how they shift, is what converts patent data into strategic positioning.

Why energy patenting is surging

Transport electrification. The transition to electric vehicles drives intense filing in battery chemistries, energy density, fast charging, safety, and manufacturing.

Grid decarbonization. Balancing intermittent renewables requires storage, which drives filing in grid-scale and long-duration technologies.

Long-duration storage demand. Storing energy over many hours or seasonally has pushed activity into flow, compressed-air, iron-air, thermal, and hydrogen routes at differing readiness levels.

Materials and interface innovation. Much of the activity is in materials and interfaces, from solid electrolytes and metal hydrides to electrode-electrolyte engineering, where the underlying research is published before it is patented.

Publication lag. The most recent filings are under-represented because applications publish about eighteen months after their priority date, so current activity is larger than the latest figures show.

How to run an energy patent landscape and white space analysis

Scope the technology space with classification codes, selecting the relevant Cooperative Patent Classification and International Patent Classification categories for the storage routes and sub-classes in view, so the boundary is standardized and reproducible.

Aggregate to the patent-family level, so international coverage of a single invention is not double-counted and volume reflects distinct R&D.

Segment by technology route, separating lithium-ion, solid-state and its electrolyte classes, metal-hydride hydrogen storage, and the long-duration routes, since each is at a different readiness level and must be assessed on its own terms.

Cluster activity by concept using semantic analysis over classification and text, so related work groups together across the varied terminology of materials, chemistries, and architectures.

Map the dense and sparse regions and attribute activity to canonical organizations, identifying crowded sub-classes and open white space and resolving assignee variants to single entities.

Correct for publication lag and monitor continuously, discounting the most recent windows and tracking the landscape over time, because a static snapshot ages quickly in a fast-moving field.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving fields such as the energy transition across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. That structure lets Cypris segment energy-storage activity by technology route and cluster it by concept across the varied terminology of materials, chemistries, and architectures, so a team can resolve which routes and sub-classes are crowded and which remain open as white space. Dense semantic search across patents and scientific literature connects filings to the underlying materials and interface research, which matters in energy storage because the earliest signals appear in the literature before patents. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the classification, clustering, attribution, and gap analysis. Agentic Monitoring tracks a defined storage route over time and flags new patents and papers as they publish, which is essential where recent activity is under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is energy storage one of the fastest-growing patent areas?

Energy storage is one of the fastest-growing patent areas because of transport electrification, grid decarbonization, and the need for long-duration storage. A joint IEA and EPO analysis found battery and electricity-storage patenting grew about 14 percent per year from 2005 to 2018, roughly four times the all-technology average, across more than 65,000 international patent families. More recent IEA analysis reports that batteries now dominate the energy patent landscape.

What technology routes does the energy-storage patent landscape cover?

The energy-storage patent landscape covers several competing routes at different readiness levels, including lithium-ion, solid-state batteries with sulfide, oxide, polymer, and composite electrolytes, metal-hydride hydrogen storage, and long-duration routes such as flow, compressed-air, iron-air, thermal, and gravity storage. Each is a distinct route with its own activity level and technical barriers. A landscape analysis segments these rather than treating storage as one field.

What is a patent landscape analysis for the energy transition?

A patent landscape analysis for the energy transition maps where filing activity concentrates across energy-storage routes, which sub-classes are crowded, and which organizations are most active, scoped by classification codes and aggregated to the patent-family level. It gives R&D and IP teams a structured, reproducible view of a fast-moving field. Paired with white space analysis, it also identifies the sparse regions where a defensible position is still available.

How do you find white space in energy-storage patents?

‍Finding white space in energy-storage patents means mapping patents and scientific literature across the routes, clustering activity by concept, and identifying the sparse sub-classes where few patents exist. Because materials and interface research is published before it is patented, literature coverage reveals white space earlier. The sparse regions indicate directions where a team can still build a novel, defensible position.

Why use classification codes and patent families in an energy landscape?

Classification codes scope the technology space in a standardized, reproducible way independent of applicant terminology, and patent-family aggregation avoids double-counting the multiple international applications a single invention generates. Together they make the landscape accurate and comparable across competitors. Keyword-only scoping and document-level counting distort both boundary and volume.

What are the main technical barriers in solid-state batteries?

The main technical barriers in solid-state batteries are interfacial resistance and stability at the electrode-electrolyte interfaces, dendrite suppression, and scalable synthesis and manufacturing of the solid electrolyte. Sulfide electrolytes reach ionic conductivities comparable to liquid electrolytes, so the current focus has shifted from materials discovery toward interface engineering and manufacturing. Patent activity reflects this shift.

Why does publication lag matter in energy patent landscapes? Publication lag matters because applications publish about eighteen months after their priority date, so the most recent filing activity is under-represented in current data. In a fast-moving field like energy storage, apparent softness in the latest window is usually an artifact of lag rather than a real slowdown. Longer-window trends and continuous monitoring are more reliable than the latest figures alone.

Why does energy patent analysis need scientific literature?

‍Energy patent analysis needs scientific literature because much of the innovation is in materials and interfaces, which are typically published in research before they are patented. Analyzing patents alone gives a lagging view, while adding literature reveals emerging activity earlier. Cypris analyzes both across more than 500 million patents and scientific papers.

How do you keep an energy patent landscape current?

Keeping an energy patent landscape current requires continuous monitoring, because the field moves quickly, new filings and research publish constantly, and publication lag hides the most recent activity. A one-time landscape ages fast. Cypris uses Agentic Monitoring to track a defined storage route over time and flag new patents and papers as they publish.

Who uses patent landscape analysis for the energy transition?

Patent landscape analysis for the energy transition is used by R&D, innovation, IP, and strategy teams at battery makers, automotive and energy companies, materials developers, and their partners. It informs where to invest, where to file, and where competitors are concentrating. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

Works Cited

1. International Energy Agency & European Patent Office (2020). Innovation in Batteries and Electricity Storage: A Global Analysis Based on Patent Data. https://www.iea.org/reports/innovation-in-batteries-and-electricity-storage
2. International Energy Agency (2026). The State of Energy Innovation 2026. https://www.iea.org/reports/the-state-of-energy-innovation-2026
3. Kim, J.-J. et al. (2026). Key Challenges and Strategies for Commercialization of All-Solid-State Batteries: Materials, Interface Engineering, and Manufacturing Processes. International Journal of Energy Research. https://doi.org/10.1155/er/8704807
4. Liu, Q. et al. (2023). Interfacial Modification, Electrode/Solid-Electrolyte Engineering, and Monolithic Construction of Solid-State Batteries. Electrochemical Energy Reviews. https://doi.org/10.1007/s41918-022-00167-1
5. Gamo, H., Nagai, A. & Matsuda, A. (2023). Toward Scalable Liquid-Phase Synthesis of Sulfide Solid Electrolytes for All-Solid-State Batteries. Batteries. https://doi.org/10.3390/batteries9070355

‍

The Model Context Protocol has become the connective tissue between AI assistants and the specialized data that R&D and IP teams depend on. Instead of copying patent claims into a chat window or pasting abstracts from a database, a team can connect an AI client directly to patent and scientific literature sources and work in natural language. But 2026 has surfaced a sharper distinction than "which server connects to which database." The more important question for innovation leaders is whether a server is a single-source connector or a domain-oriented intelligence layer built to support the actual decisions in an R&D and IP stage-gate process. This ranked guide covers the most capable options available today, leading with the one built for end-to-end R&D workflows and following with the strongest open-source connectors for teams assembling their own stack.

A note on method before the list. Every open-source server below is a real, publicly available project with a verifiable repository or registry listing. The ranking weighs how well a server supports actual R&D and IP decisions, alongside breadth of data coverage, depth of available tools, maintenance signals, and usability for a non-developer working through an AI client rather than the command line.

1. Cypris

Most MCP servers in this space answer a narrow question: search this database, retrieve that document. Cypris approaches the problem from the opposite direction, as a domain-oriented intelligence layer designed for the agents that map to real R&D and IP stage gates rather than for one-off lookups. The distinction matters because innovation decisions are not single queries; they are structured workflows where prior art, white space, freedom to operate, and regulatory signals each gate a project's progress.

That orientation is what sets it at the top of this list. Cypris is built to support prior art agents that surface relevant disclosures before a program commits resources, white space agents that identify uncontested technical territory, freedom-to-operate agents that flag blocking risk, and regulatory agents that track the filings and approvals shaping a field. It draws on a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology, so an agent reasons over structured domain context rather than raw search hits. Cypris Q, the platform's agentic layer, and enterprise API partnerships with OpenAI, Anthropic, and Google are what make this accessible to Fortune 500 R&D teams inside their own AI environments. It meets enterprise-grade security requirements, which is the threshold for deployment at that scale. For organizations whose AI agents need to fit the stage-gate process rather than just query a database, this is the layer built for the job.

2. USPTO Patent MCP Server (riemannzeta/patent_mcp_server)

The most substantial single-source connector in the public ecosystem. It is a FastMCP server for accessing United States Patent and Trademark Office patent and application data through the Patent Public Search API, the Open Data Portal API, PTAB API v3, and Patent Litigation APIs, letting an AI client search granted patents and applications, work through PTAB proceedings, analyze litigation, and research prosecution history. GitHub

What earns it credibility is its transparency about API churn. It provides 52 tools across 6 USPTO data sources, of which 27 are active and 25 are unavailable due to API shutdowns. Notably, the PatentsView API was shut down on March 20, 2026 with data migrated to ODP bulk datasets, and the Office Action and Enriched Citation APIs were decommissioned in early 2026. The affected tools remain registered and return workaround guidance rather than failing silently. For US-centric patent work assembled in-house, this is the strongest starting point. GitHubGitHub

3. OpenPharma Patents MCP (openpharma-org/patents-mcp)

Broader in geography than the USPTO server. It accesses patent data from multiple sources including the USPTO and Google Patents, offering Patent Public Search, the Open Data Portal for metadata and assignment data, and Google Patents access to 90 million-plus publications across 17-plus countries via Google BigQuery, spanning US, EP, WO, JP, CN, KR, GB, DE, FR, CA, AU and more. The tradeoff is setup friction: the Google Patents tools require a Google Cloud project with BigQuery access and a service account key, and the ODP tools require a USPTO API key. That puts full functionality slightly beyond a non-technical user, but for global patent landscape work the breadth is hard to match. GitHub + 2

4. Patent Connector (patent.dev)

The most approachable option for European coverage. It is a Model Context Protocol server in open beta that connects ChatGPT Desktop, Claude Desktop, and other MCP-compatible tools directly to patent databases, starting with the free EPO Open Patent Services API, with data drawn from the EPO's bibliographic, legal event, full-text and image databases, the same sources behind Espacenet and the European Patent Register. The EPO OPS API is free to use after registering for credentials, with a non-paying tier available. Its accuracy argument is genuine: general tools reaching Google Patents through web search tend to confuse filing and publication dates or extract incomplete claim text, which a dedicated retrieval layer avoids. Patent + 2

5. Google Patents MCP (KunihiroS/google-patents-mcp)

A focused single-purpose server. It searches Google Patents via the SerpApi Google Patents API and can be installed for Claude Desktop automatically via Smithery, requiring a SerpApi API key provided as an environment variable. It supports filtering by country and other parameters. The dependency on a third-party paid API is the main consideration, but for natural-language Google Patents search it does one job well. GitHubGitHub

6. Paper Search MCP (openags/paper-search-mcp)

Crossing into scientific literature, this is the broadest paper-retrieval server available. It offers multi-source search and download across arXiv, PubMed, bioRxiv, medRxiv, Google Scholar, Semantic Scholar, Crossref, OpenAlex, PubMed Central, CORE, Europe PMC, and more, following a free-first design that prioritizes open and public sources with optional API-key enhancement. For literature coverage breadth, nothing else in the open ecosystem comes close. MCP ServersMCP Servers

7. Academic MCP Server (nanyang12138/Academic-MCP-Server)

A solid scientific-literature connector. It supports six databases: PubMed, bioRxiv, medRxiv, arXiv, Semantic Scholar, and Sci-Hub, with advanced search by title, author, and date range. A practical caveat for enterprise use: the Sci-Hub integration carries copyright considerations, and teams should rely on the legitimate sources and obtain papers through proper channels. GitHub

8. Academia MCP (IlyaGusev/academia_mcp)

The most workflow-oriented of the open paper servers. It searches across arXiv, ACL Anthology, HuggingFace Datasets, and Semantic Scholar, and adds tools to list citing and referenced papers, download and review PDFs, and answer questions over document chunks, though the LLM-powered tools require an OpenRouter API key. For literature-review workflows rather than plain retrieval, it's the most capable open option. MCP ServersMCP Servers

How to choose

The open-source servers in positions two through eight are excellent point connectors: pick one by the database you need and the client you use, and accept that you are assembling and maintaining the integration yourself. The reason Cypris leads is that an R&D organization rarely needs a single database; it needs agents that carry domain context across the prior art, white space, freedom-to-operate, and regulatory decisions that gate a program. That is an intelligence-layer problem, not a connector problem, which is the line separating the top of this list from the rest of it.

Frequently Asked Questions

What is an MCP server for patents and papers?An MCP server is a connector built on the Model Context Protocol that links an AI client such as Claude Desktop or ChatGPT Desktop directly to a data source. For patents and papers, that means an AI assistant can search and retrieve patent documents, claims, and scientific literature in natural language, without a user manually copying results between a database and a chat window. Most public servers connect to a single source or family of sources; a smaller number act as broader intelligence layers that support full R&D workflows.

What is the best MCP server for R&D and IP workflows in 2026?For end-to-end R&D and IP work, Cypris is built specifically for the agents that map to stage-gate decisions: prior art, white space, freedom to operate, and regulatory analysis. It functions as a domain-oriented intelligence layer over a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology, rather than as a single-database connector. For teams that need a connector to one specific source, the strongest open-source options are the USPTO Patent MCP Server for US data and Paper Search MCP for scientific literature.

Is there an MCP server that covers both patents and scientific papers?Yes, in two senses. Cypris spans both patents and scientific papers within a single intelligence layer built for R&D decisions. Among open-source connectors, the breadth is usually split: patent servers like OpenPharma Patents MCP focus on patent sources, while paper servers like Paper Search MCP cover scientific literature. Teams assembling their own stack often run one of each.

What is the most capable open-source patent MCP server?The USPTO Patent MCP Server is the deepest single-source option. It accesses USPTO data through the Patent Public Search API, the Open Data Portal API, PTAB API v3, and litigation APIs, supporting patent search, PTAB proceedings, litigation analysis, and prosecution history research. Its maintainers are transparent that a portion of its tools are currently inactive due to USPTO API shutdowns in early 2026, which is a useful signal of honest maintenance.

Which MCP server is best for European patent data?Patent Connector is the most approachable option for European coverage. It connects MCP-compatible clients to the EPO's Open Patent Services API, drawing on the same bibliographic, legal-event, full-text, and image databases that power Espacenet and the European Patent Register. The EPO OPS API is free to use after registering for credentials, with a non-paying tier available.

Which MCP server covers the most scientific literature sources?Paper Search MCP has the broadest coverage, spanning arXiv, PubMed, bioRxiv, medRxiv, Google Scholar, Semantic Scholar, Crossref, OpenAlex, PubMed Central, CORE, Europe PMC, and more. It uses a free-first design that prioritizes open sources, with optional API keys to raise rate limits on services like Semantic Scholar.

Do MCP servers for patents require API keys?It varies. Some, like Patent Connector using the EPO's free OPS tier, work with free credentials. Others require paid third-party keys, such as the Google Patents MCP server's dependency on a SerpApi key, or cloud setup, such as OpenPharma's need for a Google Cloud BigQuery project and a USPTO Open Data Portal key. Enterprise platforms like Cypris are accessed through enterprise API arrangements rather than self-service keys.

What is the difference between a single-source connector and an intelligence layer?A single-source connector answers a narrow question: search this database, return these documents. An intelligence layer is built to support a structured decision process, where domain context carries across multiple linked questions. In R&D and IP, those questions are the stage gates, prior art, white space, freedom to operate, and regulatory, and an intelligence layer like Cypris is designed so agents reason across them rather than treating each as an isolated lookup.

Can these MCP servers handle freedom-to-operate or white space analysis?The open-source connectors retrieve the underlying data a human or agent would need, but they do not themselves perform freedom-to-operate or white space analysis; that logic sits with whatever agent or analyst uses them. Cypris is built the other way around, with agents oriented to those specific analyses, drawing on its ontology-structured corpus to support the decision rather than just return search results.

How should an R&D team choose among these servers?Teams that need a single database and are comfortable building and maintaining an integration should pick an open-source connector by source and client compatibility. Teams that need agents to carry domain context across the full R&D and IP stage-gate process, rather than querying one source at a time, should evaluate an intelligence layer such as Cypris. The deciding question is whether the need is retrieval from one source or reasoning across a workflow.

‍

Radioligand therapy has become one of the fastest-growing modalities in oncology, and its patent landscape is distinctive because a radiopharmaceutical is a modular product assembled from independently patentable parts. A radioligand therapy joins a radioactive isotope to a targeting molecule, an antibody, peptide, or small molecule that homes to a tumor marker, through a chelator that holds the isotope and a linker that connects the pieces, and it is delivered under a specific dosing regimen and produced by a specialized, time-critical manufacturing process. Peer-reviewed analyses of the modality describe exactly this layered structure, spanning the radioisotope and its decay-chain radiochemistry and quality control, the chelator, and the targeting vector.¹,²,³ A notable feature of the record is that most patent families in this space disclose the vector, the radiolabel, and the chelator together rather than in isolation, so the layers, while conceptually distinct, are rarely cleanly separated, which is itself a landscape finding. Because these elements can nonetheless be claimed separately and are often held by different owners, freedom-to-operate for a new radioligand therapy is a multi-layer, multi-owner analysis rather than a single clearance.

The commercial and deal environment has raised the stakes across every layer. The approval and rapid uptake of the first marketed radioligand therapies validated the model: Lutathera (lutetium-177 dotatate) was approved in 2017 in the European Union and 2018 in the United States and expanded to pediatric patients aged twelve and older with gastroenteropancreatic neuroendocrine tumors in April 2024,⁴ and Pluvicto (lutetium-177 vipivotide tetraxetan) received initial US approval in 2022.⁵ A wave of multi-billion-dollar acquisitions followed as large pharmaceutical companies, including Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Novartis, bought their way into targeting platforms and, increasingly, into isotope access; Bristol Myers Squibb's all-cash acquisition of RayzeBio, at roughly $4.1 billion in equity value ($62.50 per share), is representative of the scale of the deals.⁶ Because radiopharmaceuticals decay on a clock, the supply and quality control of the isotope, particularly short-lived alpha-emitters, has become a strategic constraint, and it remains a named bottleneck in the peer-reviewed literature.³ The patent picture reflects both the therapy and the infrastructure around it: across the Cypris corpus of more than 500 million patents and scientific papers, the radioligand- and radionuclide-therapy space holds roughly 25,600 de-duplicated families and has grown about 2.8 times from 2015 to 2024, with the United States far in front on geography, followed by Germany, Switzerland, and China, and the most active assignees spanning pharmaceutical companies, imaging and isotope suppliers, and academic medical centers. Because applications publish about eighteen months after filing, the newest chelator, ligand, and manufacturing filings are under-represented (2025 and 2026 counts are partial), so the current frontier is more active than granted-patent counts suggest.

The strategic picture turns on two shifts. First, the field is moving from beta-emitting isotopes toward more potent, shorter-range alpha-emitters such as actinium-225, whose high-energy, short-range emissions can raise tumor cell kill while limiting marrow toxicity.⁷,⁸,⁹ That shift is visible but still early in the patent record: across the Cypris corpus, the beta-emitter slice outweighs the alpha-emitter slice by roughly 1.8 to 1 on an indicative basis, so the field remains beta-dominant even as the alpha share rises quickly. The shift also changes the IP, because the chelators, purification methods, and supply chains for alpha-emitters are distinct and less mature; specialized macrocyclic chelators developed for actinium, and computational chelator-design methods, define much of this layer, and theranostic chelators that pair imaging and therapy add another dimension.¹⁰,¹¹,¹² Second, because a working therapy requires rights across the isotope, the chelator, the ligand, and the manufacturing chain, licensing structure matters as much as claim scope, and newer targeting vectors, such as somatostatin-receptor agonists and antagonists for neuroendocrine tumors, open fresh ligand-layer positions.¹³ Reading the landscape by layer and by owner, and tracking both the patents and the underlying chemistry and nuclear-medicine research, is what separates a workable position from a blocked one.

What creates FTO risk in radioligand therapy

Isotope and isotope-production claims. These cover the radioisotope and the methods to produce, purify, and quality-control it, an increasingly contested layer as alpha-emitter supply becomes a bottleneck.²,³

Chelator and linker claims. These cover the chemistry that holds the isotope and connects it to the targeting molecule, a distinct and heavily engineered layer, especially for alpha-emitters.¹⁰

Targeting ligand claims. These cover the antibody, peptide, or small molecule that directs the therapy to a tumor marker, often the most visible layer and a frequent source of competition.¹³

Combination and regimen claims. These cover pairings with other agents and specific dosing schedules, which can independently block a competing label.

Manufacturing and supply-chain claims. These cover the time-critical production, formulation, and distribution of a decaying product, where practical, hard-to-design-around barriers concentrate.³

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, supply-constrained landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant isotope, chelator, ligand, combination, and manufacturing claims regardless of terminology, attribution that resolves the many owners and the license and acquisition chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings, supply agreements, and deals. Because radiopharmaceutical advances appear in scientific and nuclear-medicine literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as radioligand therapy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, isotope, chelator, targeting ligand, combination, and manufacturing, and normalizes owners and their acquisition chains to canonical entities, so a team sees how rights and isotope access are distributed across many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying chemistry and nuclear-medicine research, which is where new chelators, alpha-emitter methods, and ligands emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for radioligand therapy? Freedom-to-operate is hard for radioligand therapy because a radiopharmaceutical is assembled from several independently patentable layers, the isotope, the chelator, the targeting ligand, the combination regimen, and the manufacturing and supply chain, often held by different owners. In practice most filings disclose several layers together. FTO is therefore a multi-layer, multi-owner analysis that must also account for isotope access.

Why is isotope supply a strategic issue? Isotope supply is strategic because radiopharmaceuticals decay on a clock, so a therapy is only viable if the isotope can be produced, purified, and delivered on time, and the supply of short-lived alpha-emitters is constrained. The preparation and quality control of actinium-225 in particular remain named bottlenecks in the literature. The isotope-production and purification layer is increasingly patented and contested.

What claim types create FTO risk in radioligand therapy? Five claim types create FTO risk: isotope and isotope-production claims, chelator and linker claims, targeting ligand claims, combination and regimen claims, and manufacturing and supply-chain claims. Each covers a distinct layer and can be held by a different owner. The chelator and isotope-production layers are especially decisive for alpha-emitters.

Why is the shift from beta to alpha emitters important? The shift matters because alpha-emitters are more potent over a shorter range, but their chelators, purification methods, and supply chains are distinct and less mature than those for beta-emitters. In the patent record the field is still beta-dominant, with alpha rising quickly. That immaturity opens white space for developers who solve the chemistry and supply problems.

Where is the white space in radiopharmaceuticals? The white space sits in alpha-emitter chelators and purification, isotope-production methods, novel targeting ligands for markers beyond the most crowded targets, and time-critical manufacturing and distribution. The leading targets and beta-emitter chemistries are comparatively crowded. The higher-value opportunities are in the alpha-emitter and supply layers.

Why does radiopharmaceutical analysis need scientific literature? Radiopharmaceutical analysis needs scientific literature because chelator, isotope, and ligand advances appear in chemistry and nuclear-medicine research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the radiopharmaceutical patent landscape? Software for the radiopharmaceutical landscape should resolve owners, acquisition chains, and isotope access to canonical entities, cluster the isotope, chelator, ligand, and manufacturing layers, search patents and scientific literature semantically, and monitor deals and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need radiopharmaceutical patent landscape and FTO analysis? Radiopharmaceutical patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at radiopharma and oncology companies, isotope producers, and their partners, as well as investors assessing radioligand assets. The modular, supply-constrained, deal-driven landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Andrade, D. B., Chen, S., Lee, S. T., Vallis, K. A., et al. (2024). A meta-analysis and meta-regression of PSMA radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer. European Urology. https://doi.org/10.1016/j.eururo.2024.09.020
2. Seimbille, Y., de Blois, E., Morgenstern, A., et al. (2025). Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE. EJNMMI Radiopharmacy and Chemistry, 10. https://doi.org/10.1186/s41181-025-00332-z
3. Duatti, A. (2025). Open problems for the preparation and quality control of Ac-225 radiopharmaceuticals. Current Radiopharmaceuticals. https://doi.org/10.1016/j.craph.2025.100004
4. U.S. Food and Drug Administration (2024, April 23). FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets
5. U.S. Food and Drug Administration (2022). PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf
6. Bristol Myers Squibb (2023). Broadening our oncology capabilities with the acquisition of RayzeBio (Exhibit 99.1), U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/14272/000114036123059406/ny20017436x1_ex99-1.htm
7. Bishnoi, K., Panda, A. K., Parida, G. K., & Agrawal, K. (2023). Efficacy and safety of Ac-225 PSMA radioligand therapy in metastatic prostate cancer: a systematic review and meta-analysis. Medical Principles and Practice, 32(3). https://doi.org/10.1159/000531246
8. Pini, C., Gelardi, F., Gandaglia, G., et al. (2025). Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer — systematic review and meta-analysis. Theranostics, 15. https://doi.org/10.7150/thno.106574
9. Treglia, G., Impériale, A., Paone, G., et al. (2025). Efficacy and safety of radioligand therapy with actinium-225 DOTATATE in neuroendocrine neoplasms: a systematic review and meta-analysis. Medicina, 61(8), 1341. https://doi.org/10.3390/medicina61081341
10. Thiele, N. A., Radchenko, V., Ramogida, C. F., Wilson, J. J., et al. (2017). An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angewandte Chemie International Edition, 56(46). https://doi.org/10.1002/anie.201709532
11. Stein, B. W., Lilley, L. M., Batista, E. R., et al. (2020). Computer-assisted design of macrocyclic chelators for actinium-225 radiotherapeutics. Inorganic Chemistry, 59(21). https://doi.org/10.1021/acs.inorgchem.0c02432
12. Comba, P., Zarschler, K., Stephan, H., et al. (2022). Toward personalized medicine: one chelator for imaging and therapy with lutetium-177 and actinium-225. Journal of the American Chemical Society, 144(41). https://doi.org/10.1021/jacs.2c08438
13. Jakobsson, V., Baum, R. P., Greifenstein, L., Zhang, J., et al. (2022). Alpha-PRRT using actinium-225-labeled somatostatin receptor agonists and antagonists. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.1034315

‍

Artificial intelligence has become a permanent layer in pharmaceutical R&D, and it is generating a distinctive, fast-growing patent landscape. The convergence of AI and drug discovery is visible directly in the data on generative-AI patenting: among the categories tracked by the World Intellectual Property Organization, applications in molecules, genes, and proteins, though smaller in absolute number at roughly 1,500 inventions, were the fastest-growing, expanding at about 78 percent per year over a five-year period.¹ Peer-reviewed patent-basis analysis of AI in the pharmaceutical industry confirms both the rapid rise of filing activity and its concentration among a set of key players,² and a growing body of work applies patent-landscaping and bibliometric methods specifically to AI-driven drug discovery, including in areas such as cancer drug discovery.⁵,⁶,⁷ For R&D and IP teams, the strategic questions are which sub-domains are crowded, where defensible white space remains, and how the unsettled rules on AI-assisted inventorship affect what can be protected.

The landscape divides into several technically distinct sub-domains, each a different region of patenting. Generative molecular design covers models that propose novel candidate molecules. Drug-target interaction and binding-affinity prediction covers models that predict whether and how strongly a molecule binds a target. Drug repurposing covers methods that use biomedical knowledge graphs and network pharmacology to find new uses for known compounds. Multi-omics response prediction covers models that predict biological response from genomic and other omics data. Clinical-trial prediction and design covers models that forecast trial success and optimize design. And a further layer covers AI-assisted pharmaceutical development and, increasingly, generative AI applied to regulatory documentation. These sub-domains differ sharply in how crowded they are: biomedical knowledge-graph construction and traversal, for example, has become a comparatively crowded area of prior art, while newer large-language-model-native and agentic approaches are earlier and sparser.

Two structural features shape the landscape. The first is geographic and institutional concentration: the same concentration seen across generative AI, where a small number of countries account for most filings, extends into AI drug discovery, with China's share of generative-AI patenting near the top globally.¹ The second is the unsettled status of AI-assisted inventorship. In the United States, the Patent and Trademark Office rescinded its February 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard, which affects how AI-heavy pipelines document invention and how their patents should be valued.³ Commentators expect the first wave of litigation over AI-generated drug inventions within a few years, which will set precedents on inventorship and eligibility.⁴ These are not peripheral legal details; they determine what portion of an AI-driven discovery effort can be protected and how a portfolio should be structured, and they vary by jurisdiction. Because applications publish about eighteen months after filing, the newest large-language-model-native and agentic filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What the AI drug discovery landscape shows

Fastest-growing generative-AI category. Among generative-AI patents, molecule, gene, and protein applications grew fastest, at roughly 78 percent per year, though from a smaller base than image or text applications.¹

Several distinct sub-domains. The field spans generative molecular design, drug-target interaction prediction, knowledge-graph-based repurposing, multi-omics response prediction, clinical-trial prediction, and AI-assisted development.²

Crowded versus sparse areas. Biomedical knowledge-graph construction and traversal is comparatively crowded prior art, while large-language-model-native and agentic approaches are earlier and sparser.

Geographic concentration. Activity is concentrated in a small number of countries, mirroring the broader generative-AI landscape, with China prominent.¹

Unsettled inventorship. AI-assisted inventorship rules are in flux, with the US returning to a human-conception standard in late 2025, which affects what can be protected and how portfolios are documented.³,⁴

How AI-powered landscape and white space analysis helps

Mapping a fast-moving, sub-domain-structured field where much of the state of the art is in non-patent literature requires more than keyword search. AI-powered analysis addresses this with semantic search across both patents and scientific literature, which is essential because AI-method disclosures often appear first in preprints and conference proceedings, attribution that normalizes filers to canonical entities, and continuous monitoring that tracks the newest agentic and large-language-model-native filings. Clustering activity by sub-domain and by concept is what distinguishes crowded prior art from genuine white space.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving, literature-heavy fields such as AI in drug discovery across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. Because the corpus spans both patents and scientific literature, Cypris covers the preprints and conference proceedings where AI-method disclosures often appear first, rather than patents alone. The ontology clusters activity by sub-domain, generative design, interaction prediction, repurposing, multi-omics, and clinical prediction, and normalizes filers to canonical entities, so a team can resolve which areas, such as knowledge-graph methods, are crowded and which, such as agentic approaches, remain open as white space. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined area over time and flags new patents and papers as they publish, which is essential where the newest filings are under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is AI drug discovery patenting growing?

AI drug discovery patenting is growing quickly. Among generative-AI patent categories tracked by WIPO, applications in molecules, genes, and proteins were the fastest-growing at roughly 78 percent per year, though from a smaller base than image or text applications. Peer-reviewed patent-basis analysis confirms the rapid rise of AI filing activity in the pharmaceutical industry.

What are the main sub-domains of AI drug discovery patents?

The main sub-domains are generative molecular design, drug-target interaction and binding-affinity prediction, drug repurposing using biomedical knowledge graphs, multi-omics response prediction, clinical-trial prediction and design, and AI-assisted pharmaceutical development. Each is a technically distinct region of the patent landscape. They differ substantially in how crowded they are.

Which areas of AI drug discovery are crowded, and which are open?

Biomedical knowledge-graph construction and traversal has become a comparatively crowded area of prior art in AI drug discovery, while large-language-model-native and agentic approaches are earlier and sparser. The crowded areas carry more freedom-to-operate risk, and the sparser areas hold more white space. Distinguishing them requires clustering activity by sub-domain and concept.

How does AI-assisted inventorship affect drug patents?

AI-assisted inventorship affects drug patents because the rules on whether and how AI-assisted inventions can be protected are unsettled and vary by jurisdiction. In the United States, the Patent and Trademark Office rescinded its 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard. This affects how AI-heavy pipelines document invention and how their patents are valued.

Why does China feature prominently in AI drug discovery patenting?

China features prominently in AI drug discovery patenting because it accounts for a large share of generative-AI patenting overall, and that concentration extends into the drug discovery sub-domains. The broader generative-AI landscape is dominated by a small number of countries. This geographic concentration matters for competitive positioning and freedom-to-operate.

Why does AI drug discovery analysis need scientific literature?

AI drug discovery analysis needs scientific literature because AI-method disclosures often appear first in preprints and conference proceedings rather than patents, so a patent-only view misses much of the state of the art. This is characteristic of AI fields generally. Cypris analyzes both patents and scientific literature across more than 500 million documents.

How do you find white space in AI drug discovery?

Finding white space in AI drug discovery means clustering activity by sub-domain and concept across patents and scientific literature, and identifying the sparser areas, such as agentic and large-language-model-native approaches, where few patents yet exist. Because much of the state of the art is in non-patent literature, semantic search across both sources is essential. The white space is where a viable method exists but patenting is still thin.

Which teams use AI drug discovery patent landscape analysis?

AI drug discovery patent landscape analysis is used by R&D, IP, and strategy teams at pharmaceutical companies, AI-native drug discovery firms, and their partners, as well as investors assessing AI-driven pipelines. It informs where to file, where freedom-to-operate risk sits, and how to structure a portfolio given inventorship uncertainty. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an AI drug discovery landscape need to be?

An AI drug discovery landscape needs to be continuously current, because the field moves quickly, inventorship rules are shifting, new agentic and large-language-model-native filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages within months. Cypris uses Agentic Monitoring to track a defined area and flag new patents and papers as they publish.

Endnotes

1. World Intellectual Property Organization (2024). Patent Landscape Report: Generative Artificial Intelligence. Geneva: WIPO. https://doi.org/10.34667/tind.49740
2. Kano, S. & Sakaoka, S. (2025). Quantitative insights on artificial intelligence in the pharmaceutical industry: a patent-basis analysis of technological trends and key players. World Patent Information. https://www.sciencedirect.com/science/article/pii/S0172219025000481
3. United States Patent and Trademark Office (2025). Revised Inventorship Guidance for AI-Assisted Inventions, Federal Register (published November 28, 2025; rescinding the February 2024 guidance and returning to the traditional human-conception standard). https://www.federalregister.gov/documents/2025/11/28/2025-21457/revised-inventorship-guidance-for-ai-assisted-inventions
4. Goodwin (2026). AI Drug Discovery Tests the Limits of Patent Law. https://www.goodwinlaw.com/en/insights/publications/2025/12/insights-lifesciences-ip-ai-drug-discovery-tests-the-limits-of-patent-law
5. Hofmann-Apitius, M., Gadiya, Y., Zaliani, A. & Gribbon, P. (2023). Pharmaceutical patent landscaping: a novel approach to understand patents from the drug discovery perspective. Artificial Intelligence in the Life Sciences. https://doi.org/10.1016/j.ailsci.2023.100061
6. Abdulwahab, A. A. et al. (2024). Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency. Pharmaceutical Patent Analyst.
7. Jing, F. & Ma, Y. (2024). Bibliometric Analysis and Research Trends in Artificial Intelligence for Pharmaceutical Management and Drug Discovery.

‍

The CRISPR and gene-editing patent landscape is one of the largest and most contested in biotechnology, and freedom-to-operate in this field is correspondingly difficult. A landscape analysis maintained by a national patent office counted roughly 23,700 CRISPR patent families as of the end of 2024, an increase of more than 6,500 families in a single year, and it identified four competing groups holding foundational claims.¹ Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims. In gene editing, the foundational rights are split across multiple owners and jurisdictions, so a developer frequently cannot clear a product by licensing from a single source and must instead assemble rights from several, with the required set depending on the application and the country.¹,²

The fragmentation traces to an unresolved priority dispute over who first applied CRISPR-Cas9 to eukaryotic cells. The two most prominent groups are the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier on one side, and the Broad Institute of MIT and Harvard on the other, with ToolGen and Sigma-Aldrich also holding foundational filings. The dispute has run through patent offices and courts for over a decade, and it remains live: in May 2025 the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had awarded priority for eukaryotic CRISPR-Cas9 to the Broad Institute, reviving the Berkeley-led group's challenge.³,⁶ In Europe, the Berkeley-led group withdrew two foundational patents in late 2024 following an unfavorable preliminary opinion, then pursued divisional claims, while ToolGen secured European positions during 2025, illustrating how the landscape continues to shift among the competing groups.²,⁷ The academic literature has tracked this contested landscape since the technology's early years, documenting both its fragmentation and the licensing complexity it creates, and has examined proposed responses such as CRISPR patent pools.⁴,⁵,⁸

The practical consequence is that gene-editing FTO is a licensing-and-landscape problem, not a single clearance. The required rights differ by use, human therapeutics, agricultural and plant applications, research tools, and diagnostics can each implicate different foundational and improvement patents, and they differ by jurisdiction, because the same dispute has resolved differently in the United States, Europe, and Asia. The uncertainty is compounded by timing: some of the earliest, broadest patents may expire before the disputes are fully resolved, which shifts value toward the dense layer of improvement patents on delivery, specificity, and newer editing systems.² Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the landscape is even larger and more active than granted-patent counts suggest.

Why CRISPR freedom-to-operate is hard

Fragmented foundational rights. Foundational claims are split across at least four groups, so clearing a product often requires multiple licenses rather than one.¹

Unresolved disputes. The priority dispute over eukaryotic CRISPR-Cas9 remains active, with a US Federal Circuit ruling in May 2025 reviving the Berkeley-led challenge, so ownership is not yet settled.³

Jurisdictional divergence. The same dispute has resolved differently across the United States, Europe, and Asia, so FTO must be assessed market-by-market.²

Application-specific rights. Human therapeutics, agriculture, research tools, and diagnostics implicate different patents, so the required license set depends on the intended use.¹

A dense improvement layer. Beyond the foundational patents, a large and growing layer of improvement patents covers delivery, specificity, base and prime editing, and newer nucleases, which is where much current FTO risk and white space now sit, including in application areas such as agricultural gene editing.⁹

How AI-powered landscape and FTO analysis helps

Navigating a landscape of more than twenty thousand families across multiple owners, applications, and jurisdictions is beyond manual search. AI-powered analysis addresses this with semantic search that retrieves relevant claims regardless of terminology, attribution that resolves owners to canonical entities so the fragmentation is visible, and continuous monitoring that tracks a fast-shifting landscape as disputes resolve and improvement patents publish. Because gene-editing advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the improvement layer is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for complex, fragmented fields such as gene editing across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by technology and application and normalizes owners to canonical entities, so a team can see how foundational and improvement rights are distributed across the four groups and the many later filers rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where the improvement layer emerges first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim analysis, and Agentic Monitoring tracks the landscape over time and flags new filings and dispute developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How large is the CRISPR patent landscape?

The CRISPR patent landscape is very large. A national patent office landscape analysis counted roughly 23,700 CRISPR patent families as of the end of 2024, up more than 6,500 in a single year. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the true landscape is even larger.

Why is freedom-to-operate hard for CRISPR?

Freedom-to-operate is hard for CRISPR because foundational rights are split across at least four competing groups and the key priority dispute remains unresolved, so a developer often cannot clear a product with a single license. The required rights also differ by application and jurisdiction. Assembling the correct set of licenses is the central FTO challenge.

What is the Broad versus UC Berkeley CRISPR dispute?

The Broad versus UC Berkeley dispute concerns who first applied CRISPR-Cas9 to eukaryotic cells, contested between the Berkeley-led group and the Broad Institute, with ToolGen and Sigma-Aldrich also holding foundational filings. In May 2025, the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had favored the Broad Institute, reviving the Berkeley-led challenge. The dispute remains unresolved.

Does CRISPR freedom-to-operate differ by country?

Yes, CRISPR freedom-to-operate differs by country, because the same foundational dispute has resolved differently in the United States, Europe, and Asia. A party may hold stronger rights in one jurisdiction than another. FTO must therefore be assessed market-by-market rather than globally.

Why might a CRISPR product need multiple licenses?

A CRISPR product may need multiple licenses because foundational rights are fragmented across several owners, and improvement patents on delivery, specificity, and newer editing systems add further layers. The required set depends on the application and jurisdiction. This is why gene-editing FTO is a licensing-and-landscape problem rather than a single clearance.

How does the improvement-patent layer affect CRISPR FTO?

The improvement-patent layer affects CRISPR FTO because, beyond the foundational patents, a large and growing set of patents covers delivery, specificity, base and prime editing, and newer nucleases. As the earliest broad patents approach expiry, value shifts toward this layer, which is where much current FTO risk and white space sit. Mapping it requires reading both patents and scientific literature.

How does scientific literature help CRISPR landscape analysis?

Scientific literature helps CRISPR landscape analysis because gene-editing advances appear in research before they are patented, so the literature gives the earliest signal of where the improvement layer is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need CRISPR patent landscape and FTO analysis?

CRISPR patent landscape and FTO analysis is needed by R&D, IP, and business-development teams in therapeutics, agriculture, industrial biotechnology, and diagnostics, along with investors assessing gene-editing assets. The fragmentation makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does a CRISPR landscape need to be?

A CRISPR landscape needs to be continuously current, because the disputes are still resolving, new improvement patents publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

Endnotes

1. Swiss Federal Institute of Intellectual Property (2025). CRISPR Technology: Patent & Licence Landscapes. https://www.ige.ch/
2. Gowling WLG (2025). Fragmented and shifting CRISPR patent landscape: global proceedings and the patent pool solution. https://gowlingwlg.com/en/insights-resources/articles/2025/crispr-patent-landscape
3. US Court of Appeals for the Federal Circuit (2025). Regents of the University of California v. Broad Institute, Inc., decided May 12, 2025. https://www.cafc.uscourts.gov/
4. Egelie, K. J., Graff, G. D., Strand, S. P. & Johansen, B. (2016). The emerging patent landscape of CRISPR-Cas gene editing technology. Nature Biotechnology. https://doi.org/10.1038/nbt.3692
5. Contreras, J. L. & Sherkow, J. S. (2017). CRISPR, surrogate licensing, and scientific discovery. Science. https://doi.org/10.1126/science.aal4222
6. Sherkow, J. S. (2025). A "Bare Hope of a Result": The Second CRISPR Patent Appeal. The CRISPR Journal (analysis of the May 12, 2025 US Federal Circuit decision).
7. Beck Greener (2025). Update on the CRISPR-Cas9 IP saga at the EPO: blows for both the Broad and CVC camps, but ToolGen ends 2025 with success. https://www.beckgreener.com/
8. Stasi, A. & Pereira Rodrigues, I. (2019). Dealing with Patent Fragmentation in Genetics: Can Patent Pools Facilitate the Development of CRISPR Gene-Editing Technology? PubMed.
9. Muhammad Adamu, U. et al. (2026). CRISPR in Wheat: Patents, Breeding Advances, and Emerging Challenges. Trends in Intellectual Property Research.

‍

Agent orchestration in Microsoft Copilot works best when the orchestrator routes to scoped, governed connections rather than pulling every source into one undifferentiated context. The architecture that holds up under real R&D workloads keeps internal confidential data and external intelligence on separate trust boundaries, lets Copilot decide which to call, and treats external R&D and IP intelligence as a domain-oriented layer rather than a raw dataset dump. This guide explains how to design that orchestration so that a research team can ask a single question and have Copilot reason across an electronic lab notebook, internal developmental records, and the external patent and scientific literature without collapsing those very different data types into one fragile prompt.

Why orchestration belongs at the Copilot layer

The orchestrator is the component that decides which tool to call, in what order, and how to combine the results. In Microsoft Copilot Studio, generative orchestration is the mode that lets an agent select among multiple registered tools at runtime based on the user's intent and each tool's description. Microsoft requires generative orchestration to be enabled before an agent can use Model Context Protocol tools at all, which means the orchestration decision and the tool connections are designed to work as one system rather than as a hardcoded pipeline.

Putting orchestration at the Copilot layer matters for a specific reason. When orchestration is centralized, each connected source can stay narrow. The electronic lab notebook tool returns experimental records. The internal data tool returns developmental project context. The external intelligence tool returns patent and scientific findings. Copilot composes the answer from those scoped returns. The alternative, loading all of those corpora into a single context window and asking the model to sort it out, runs directly into context rot, the well-documented effect in which model accuracy degrades as the context window fills with more material. Centralized orchestration over scoped tools is the architectural answer to that degradation.

How MCP connections work inside Copilot Studio

Model Context Protocol is an open standard, introduced by Anthropic, that defines how applications expose tools and data to large language models in a consistent way. In Copilot Studio, MCP servers are made available through the same connector infrastructure that governs other Power Platform connections, which means an MCP connection inherits enterprise security and governance controls including Virtual Network integration, Data Loss Prevention policies, and multiple authentication methods.

Adding an MCP server to a Copilot Studio agent follows a defined path. From the agent's Tools page, you select Add a tool, then New tool, then Model Context Protocol, which opens the MCP onboarding wizard. You provide a server name, a server description, and a server URL, then select the authentication type the server requires. The server description is not cosmetic. The agent orchestrator reads that description at runtime to decide whether to call the server for a given user request, so a precise description of what each connection does is part of making orchestration work correctly. Once connected, each tool the MCP server publishes becomes an action inside Copilot Studio and inherits the server's defined inputs and outputs, and Copilot Studio reflects updates automatically as tools change on the server.

One governance fact shapes the entire design. Because MCP servers in Copilot Studio rely on Power Platform connectors for connectivity, any Data Loss Prevention policy that regulates those connectors also regulates the MCP server and its tools. This is the lever that lets a security team treat an internal ELN connection and an external intelligence connection under different policies even though both reach Copilot through the same mechanism.

Designing the internal trust boundary: ELN and developmental data

Internal confidential and developmental data is the most sensitive material in the orchestration, and it should be connected under the strictest governance. Electronic lab notebooks such as Benchling, LabArchives, and Scispot store the experimental records, sample data, and process documentation that represent a research organization's most valuable and proprietary information, and these platforms expose their data through documented REST APIs and emphasize regulatory compliance and data integrity as core features.

The design principle for this boundary is least exposure. The ELN connection and any internal developmental data connection should be governed by Data Loss Prevention policies that prevent confidential records from being combined with or transmitted to external destinations. Authentication should be scoped so the agent acts with the permissions of the requesting user rather than a broad service identity, which keeps the access model aligned with who is actually allowed to see which projects. Because Copilot Studio inherits connector-level DLP, a security team can place internal connections in a data group that is policy-isolated from external connections, so that the orchestrator can read from both but the platform enforces that confidential developmental data does not leak across the boundary. The internal tools should also be described narrowly to the orchestrator, so Copilot calls them only when a request genuinely concerns internal experimental or project data.

Designing the external boundary: patent and scientific intelligence

External R&D and IP intelligence is a fundamentally different kind of input, and treating it like just another data feed is where many agent designs go wrong. There is a meaningful difference between connecting an agent to a broad external dataset and connecting it to a domain-oriented intelligence layer. A raw external MCP endpoint that exposes a large patent or literature corpus hands the orchestrator an enormous, undifferentiated body of records, and asking the model to reason over that volume reintroduces the context rot problem the orchestration was meant to avoid. A domain-oriented layer instead returns a scoped, reasoned answer to the agent, so what enters Copilot's context is already a focused intelligence result rather than thousands of raw documents.

This is where the trust boundary and the quality boundary coincide. External intelligence should never share an undifferentiated context with confidential internal data, both because of data governance and because mixing a large external corpus into the same window as sensitive internal records degrades the reasoning on both. Keeping external intelligence as a separate, scoped connection that returns reasoned findings, rather than a firehose of raw records, protects accuracy and keeps the governance boundary clean.

Cypris as the external intelligence layer

This is the role Cypris is built for. As an enterprise R&D intelligence platform, Cypris unifies more than 500 million patents and scientific papers into a single intelligence layer with a proprietary R&D ontology, so that an agent reaching for external intelligence draws on the patent and scientific record in one reasoned place rather than across siloed connectors. Cypris is designed for R&D scientists and innovation strategists rather than IP attorneys, which means the intelligence it returns is scoped to the forward-looking questions research teams actually ask.

Crucially for an orchestration design, Cypris makes that intelligence available through official enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security built to Fortune 500 requirements. That partnership model lets the Cypris intelligence layer sit behind the AI tooling an organization already uses, including a Copilot orchestration, so the external intelligence entering the agent is a reasoned domain answer rather than a raw corpus. In the orchestration described here, Copilot routes external R&D and IP questions to Cypris as the domain-oriented intelligence layer, the internal ELN and developmental connections stay on their own governed boundary, and the orchestrator composes a single answer without ever collapsing confidential internal data and the external literature into one context. That separation is what makes the whole system both secure and accurate.

Putting the orchestration together

A working design has Copilot Studio as the orchestration layer with generative orchestration enabled, internal ELN and developmental data connected as narrowly scoped tools under isolating Data Loss Prevention policies, and external patent and scientific intelligence connected as a separate domain-oriented layer through Cypris's enterprise API partnerships. Each tool carries a precise description so the orchestrator routes correctly, authentication is scoped to the requesting user, and connector-level governance keeps the internal and external boundaries policy-separated. A researcher asks one question, and Copilot pulls scoped experimental context from the ELN, scoped project context from internal records, and a reasoned external intelligence answer from Cypris, then composes a response, all without ever forcing the model to reason over one bloated, mixed context. The result is an agent that is more accurate because each input is scoped and more secure because confidential developmental data never crosses into the external boundary.

FAQ

1. Can Microsoft Copilot orchestrate across both internal and external R&D data sources?Yes. Copilot Studio's generative orchestration mode lets a single agent select among multiple registered tools at runtime based on the user's intent, so one agent can route a question to an internal electronic lab notebook, internal developmental records, and an external intelligence layer and compose a unified answer.

2. What is generative orchestration in Copilot Studio?Generative orchestration is the mode in which the Copilot agent dynamically decides which tools to call and in what order based on the user's request and each tool's description, rather than following a hardcoded sequence. Microsoft requires it to be enabled before an agent can use Model Context Protocol tools.

3. How are MCP servers connected to a Copilot Studio agent?From the agent's Tools page you select Add a tool, then New tool, then Model Context Protocol, which opens the MCP onboarding wizard. You provide a server name, description, and URL, and select the authentication type. Each tool the server publishes becomes an action in Copilot Studio.

4. How is confidential R&D data kept secure in this architecture?MCP connections in Copilot Studio run on Power Platform connector infrastructure, so they inherit enterprise controls including Virtual Network integration, Data Loss Prevention policies, and multiple authentication methods. Internal connections can be placed under DLP policies that isolate them from external connections, and authentication can be scoped to the requesting user.

5. Why keep internal and external data on separate trust boundaries?Two reasons converge. Governance requires that confidential developmental data not leak to external destinations, and accuracy requires that a large external corpus not be mixed into the same context as sensitive internal records, because filling the context window with mixed material degrades the model's reasoning on both.

6. What is context rot and why does it matter for agent design?Context rot is the documented effect in which a model's accuracy declines as its context window fills with more material. It matters because loading multiple large corpora into one prompt, rather than routing to scoped tools, makes the agent reason worse, which is the core argument for centralizing orchestration over narrow connections.

7. How do electronic lab notebooks fit into the orchestration?ELN platforms such as Benchling, LabArchives, and Scispot hold experimental records, sample data, and process documentation, and expose that data through documented REST APIs. In the orchestration they are connected as narrowly scoped internal tools under strict governance, returning only the experimental context relevant to a given request.

8. What is the difference between connecting a raw external dataset and a domain-oriented intelligence layer?A raw external endpoint hands the orchestrator a large, undifferentiated body of records, which reintroduces context rot when the model tries to reason over the volume. A domain-oriented layer returns a scoped, reasoned answer, so what enters the agent's context is a focused result rather than thousands of raw documents.

9. How does Cypris connect into a Copilot orchestration?Cypris makes its R&D intelligence available through official enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security built to Fortune 500 requirements. That model lets the Cypris intelligence layer sit behind the AI tooling an organization already uses, so Copilot can route external patent and scientific questions to Cypris and receive a reasoned domain answer.

10. What does a complete orchestration design look like?Copilot Studio serves as the orchestration layer with generative orchestration enabled, internal ELN and developmental data are connected as scoped tools under isolating DLP policies, and external patent and scientific intelligence is connected as a separate domain-oriented layer through Cypris's enterprise API partnerships, with each tool precisely described so the orchestrator routes correctly.

‍

Perovskite solar cells are among the fastest-moving areas of photovoltaics research, and the patent landscape is concentrating precisely on the problems that stand between laboratory performance and commercial deployment. Certified power conversion efficiencies for small-area single-junction perovskite cells have surpassed 27 percent, and perovskite-silicon tandem cells have surpassed 34 percent, with a widely reported tandem record of 34.6 percent set in 2024, as tracked in the authoritative certified-efficiency tables and the US National Renewable Energy Laboratory records.¹,²,³,⁴ These figures are remarkable for a technology that emerged around 2012, and they explain the intensity of research and patenting. The strategic question for R&D and IP teams is not whether perovskites can achieve high efficiency in the laboratory, that is established, but where the defensible IP positions lie on the path to durable, manufacturable modules, and that is a patent-landscape and white-space question.

The technical frontier has shifted, and the patent landscape has shifted with it. Early work concentrated on raising cell efficiency; current activity concentrates on interface engineering, charge-transport-layer design, perovskite crystallization control, and, above all, operational stability and large-area fabrication.¹ Stability under real outdoor conditions is the central barrier, and the existing photovoltaic qualification standards, developed for crystalline silicon, do not fully capture the distinct degradation modes of perovskite absorbers, so testing methodology itself is an open area.⁵ There is a well-documented gap between the efficiency of small laboratory cells and that of full-size modules, which reach roughly 23 percent, and closing that gap through scalable large-area fabrication is where much of the commercially relevant innovation now sits.¹,⁶ Newer approaches, including green-solvent processing, ambient-air fabrication, kilogram-scale synthesis of precursors, vacuum deposition, and machine-learning-assisted materials design, are accelerating the path to commercialization and defining fresh patentable territory.¹

The landscape is growing rapidly and concentrating geographically, with China prominent and a mix of academic institutions and commercial manufacturers filing; granular family counts are tracked mainly in commercial patent databases and are best treated as indicative rather than authoritative. What is clear from the technical literature is where activity is dense and where it is sparse. Dense areas include core device architectures and efficiency-oriented interface and transport-layer chemistry, which are crowded battlegrounds. Sparser, higher-value white space includes long-term encapsulation and stability, scalable large-area deposition and module integration, lead-free and alternative compositions, perovskite-specific durability testing, and tandem integration with silicon and other bottom cells. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is more active than granted-patent counts suggest.

Where the perovskite white space is

Stability and encapsulation. Long-term operational stability under outdoor conditions is the central barrier, and durable encapsulation and degradation mitigation are high-value, still-open areas.¹

Large-area manufacturing. Closing the gap between small-cell efficiency and full-module efficiency, which reaches roughly 23 percent, through scalable deposition is where much commercially relevant innovation sits.¹

Testing and durability standards. Existing photovoltaic qualification standards were developed for silicon and do not fully capture perovskite degradation, so perovskite-specific durability methodology is an open area.

Lead-free and alternative compositions. Reducing or replacing lead and engineering more stable compositions is an active, sparser area with regulatory and market drivers, and a substantial peer-reviewed literature is developing around lead-free and low-lead perovskites.⁷

Tandem integration. Integrating perovskites with silicon and other bottom cells to exceed single-junction limits is where record efficiencies are being set and where architecture-level IP is forming.²

How AI-powered landscape and white space analysis helps

Resolving dense from sparse regions across a fast-moving materials field requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by concept across the varied terminology of perovskite chemistry and device engineering, attribution that normalizes academic and commercial filers to canonical entities, and continuous monitoring that tracks a rapidly evolving frontier. Because perovskite advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier, and the white space, is moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving materials fields such as perovskite photovoltaics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by device architecture, chemistry, and the problem being solved, and normalizes academic and commercial filers to canonical entities, so a team can resolve which areas, such as core architectures and efficiency-oriented interfaces, are crowded and which, such as stability, encapsulation, and large-area manufacturing, remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying materials research, which is where the perovskite frontier moves first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined area over time and flags new patents and papers as they publish, which is essential where recent activity is under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How efficient are perovskite solar cells?

Perovskite solar cells have reached high certified efficiencies. Small-area single-junction perovskite cells have surpassed 27 percent power conversion efficiency, and perovskite-silicon tandem cells have surpassed 34 percent, with a reported tandem record of 34.6 percent in 2024. Full-size modules currently reach roughly 23 percent, and closing that gap is a central focus.

What is the main barrier to perovskite commercialization?

The main barrier to perovskite commercialization is operational stability under real outdoor conditions, alongside scalable large-area manufacturing. Existing photovoltaic qualification standards were developed for silicon and do not fully capture perovskite degradation, so durability testing is also an open problem. These barriers, rather than laboratory efficiency, define where commercially relevant innovation sits.

Where is the white space in the perovskite patent landscape?

The white space in the perovskite patent landscape is concentrated in long-term stability and encapsulation, scalable large-area deposition and module integration, lead-free and alternative compositions, perovskite-specific durability testing, and tandem integration. Core device architectures and efficiency-oriented interface chemistry are more crowded. The higher-value opportunities are in the durability and manufacturing problems that remain unsolved.

Why has perovskite patenting shifted from efficiency to stability?

Perovskite patenting has shifted from efficiency to stability because laboratory efficiency is now established at high levels, so the remaining barrier to commercialization is durability and manufacturability. Current activity concentrates on interface engineering, crystallization control, encapsulation, and large-area fabrication. The commercially relevant IP is forming around these problems.

How does tandem integration affect the landscape?

Tandem integration affects the landscape by pushing efficiency beyond single-junction limits, with perovskite-silicon tandems exceeding 34 percent. This is where record efficiencies are being set and where architecture-level IP is forming. Integration with silicon and other bottom cells is an active, strategically important area.

Why does perovskite analysis need scientific literature?

Perovskite analysis needs scientific literature because materials and device advances appear in research before they are patented, so the literature gives the earliest signal of where the frontier and the white space are moving. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Why are granular perovskite patent counts uncertain?

Granular perovskite patent counts are uncertain because they are tracked mainly in commercial patent databases and are affected by the roughly eighteen-month publication lag, which under-represents the most recent years. The most reliable signals are longer-window growth, applicant concentration, and technology-route coverage rather than the latest-year count. The field is clearly in a growth stage.

Which teams use perovskite patent landscape analysis?

Perovskite patent landscape analysis is used by R&D, innovation, IP, and strategy teams at photovoltaics manufacturers, materials developers, and their partners, as well as investors assessing the technology. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

How do you keep a perovskite landscape current?

Keeping a perovskite landscape current requires continuous monitoring, because the field moves quickly, new research and filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages within months. Cypris uses Agentic Monitoring to track a defined area and flag new patents and papers as they publish.

Endnotes

1. Nano-Micro Letters (2026). Key Advancements and Emerging Trends of Perovskite Solar Cells in 2024–2025. https://doi.org/10.1007/s40820-025-02022-6
2. CAS (a division of the American Chemical Society) (2026). Are perovskite solar panels the future of green energy? CAS Insights. https://www.cas.org/resources/cas-insights/perovskite-solar-panels
3. National Renewable Energy Laboratory. Best Research-Cell Efficiency Chart. https://www.nrel.gov/pv/cell-efficiency.html
4. Green, M. A., Dunlop, E. D., Yoshita, M. et al. (2025). Solar Cell Efficiency Tables (Version 66). Progress in Photovoltaics: Research and Applications. https://doi.org/10.1002/pip.3919
5. Stability and reliability of perovskite photovoltaics: are we there yet? (2024). PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC11985620
6. Overcoming the Challenges of Large-Area High-Efficiency Perovskite Solar Cells (large-area fabrication review). ACS Energy Letters.
7. Giustino, F. & Snaith, H. J. (2016). Toward Lead-Free Perovskite Solar Cells. ACS Energy Letters. https://doi.org/10.1021/acsenergylett.6b00499

‍